A Patient-Level Data Meta-analysis of the Abscopal Effect

Hatten, SJ, Jr; Lehrer, EJ; Liao, J; Sha, CM; Trifiletti, DM; Siva, S; McBride, SM; Palma, D; Holder, SL; Zaorsky, NG

Author(s): Hatten, SJ, Jr; Lehrer, EJ; Liao, J; Sha, CM; Trifiletti, DM; Siva, S; McBride, SM; Palma, D; Holder, SL; Zaorsky, NG;
Details: Publication Year 2022-05,Volume 7,Issue #3,Page 100909
Journal Title: Advances in Radiation Oncology
Publication Type: Review
Abstract: PURPOSE: The abscopal effect is defined when a form of local therapy causes tumor regression of both the target lesion and any untreated tumors. Herein cases of the abscopal effect were systematically reviewed and a patient-level data analysis was performed for clinical predictors of both duration of response and survival. METHODS AND MATERIALS: The Population, Intervention, Control, Outcome, Study (PICOS) design approach, Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) literature selection process, and Meta-analysis of Observational Studies in Epidemiology (MOOSE) were used to find articles published before September 2019 in MEDLINE/PubMed and Google Scholar. Inclusion criteria were (1) population: patients with reported abscopal response; (2) intervention: documented treatment(s); (3) control: none; (4) outcomes: overall and progression-free survival; and (5) setting: retrospective case reports. Time from treatment until abscopal response and time from abscopal response until progression/death were calculated. Univariate and multivariate analyses were conducted for survival outcomes. RESULTS: Fifty studies (n = 55 patients) were included. Median age was 65 years (interquartile range [IQR], 58-70) and 62% were male. Fifty-four (98%) patients received radiation therapy, 34 (62%) received radiation therapy alone, 5 (9.1%) underwent surgery, 4 (7.3%) received chemotherapy, and 11 (20%) received immunotherapy. Median total dose was 32 Gy (IQR, 25.5-48 Gy) and median dose per fraction was 3 Gy (IQR, 2-7.2). Median time until abscopal response was 4 months (IQR, 1-5; min 0.5, max 24). At 5 years, overall survival was 63% and distant progression-free survival was 45%. No variables had statistical significance in predicting duration of response or survival. CONCLUSIONS: Almost all reported cases of the abscopal response are after radiation therapy; however, there are no known predictors of duration of response or survival in this population.
Department(s): Radiation Oncology
PubMed ID: 35372719
Publisher's Version: https://doi.org/10.1016/j.adro.2022.100909
Open Access at Publisher's Site: https://doi.org/10.1016/j.adro.2022.100909
Terms of Use/Rights Notice: Refer to copyright notice on published article.

Creation Date: 2024-11-01 04:30:28

Last Modified: 2024-11-01 04:31:35